Ensysce Biosciences Inc
ENSC3.670USD
+1.800+96.26%
Cierre 04/23, 16:00（ET）Cotizaciones retrasadas 15 min
4.98MCap. mercado
PérdidaP/E TTM
Información de Ensysce Biosciences Inc Compañía
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Información de la empresa
Código de la empresaENSC
Nombre de la empresaEnsysce Biosciences Inc
Fecha de salida a bolsaDec 01, 2017
Fundada en2017
Director ejecutivoDr. Lynn D. Kirkpatrick, Ph.D.
Número de empleados7
Tipo de títulosOrdinary Share
Fin del año fiscalDec 01
Dirección7946 Ivanhoe Avenue, Suite 201
CiudadLA JOLLA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92037
Teléfono18582634196
Sitio Webhttps://ensysce.com/
Código de la empresaENSC
Fecha de salida a bolsaDec 01, 2017
Fundada en2017
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionados
Cambio
Mr. David Carl Humphrey, CPA
Mr. David Carl Humphrey, CPA
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
10.00
--
Dr. Linda Pestano, Ph.D.
Dr. Linda Pestano, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. William H.C. Chang
Mr. William H.C. Chang
Independent Director
Independent Director
--
--
Ms. Lee M. Rauch
Ms. Lee M. Rauch
Independent Director
Independent Director
--
--
Mr. Geoffrey Birkett
Mr. Geoffrey Birkett
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Lynn D. Kirkpatrick, Ph.D.
Dr. Lynn D. Kirkpatrick, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Steve R. Martin
Mr. Steve R. Martin
Independent Director
Independent Director
--
--
Bob G. Gower ,
Bob G. Gower ,
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Jeffrey Millard, Ph.D.
Dr. Jeffrey Millard, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Curtis Rosebraugh, M.D.
Dr. Curtis Rosebraugh, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionados
Cambio
Mr. David Carl Humphrey, CPA
Mr. David Carl Humphrey, CPA
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
10.00
--
Dr. Linda Pestano, Ph.D.
Dr. Linda Pestano, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. William H.C. Chang
Mr. William H.C. Chang
Independent Director
Independent Director
--
--
Ms. Lee M. Rauch
Ms. Lee M. Rauch
Independent Director
Independent Director
--
--
Mr. Geoffrey Birkett
Mr. Geoffrey Birkett
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Lynn D. Kirkpatrick, Ph.D.
Dr. Lynn D. Kirkpatrick, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Desglose de ingresos
No datos encontrados
No datos encontrados
Por negocio
Por región
No datos encontrados
Accionista
Hora de actualización: dom., 2 de mar
Hora de actualización: dom., 2 de mar
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Perceptive Advisors LLC
5.27%
Adage Capital Management, L.P.
3.04%
Gower (Robert G)
0.49%
FNY Investment Advisers LLC
0.18%
Benton (Andrew K. J.D.)
0.08%
Other
90.93%
Estadísticas de accionistas
Accionista
Proporción
Perceptive Advisors LLC
5.27%
Adage Capital Management, L.P.
3.04%
Gower (Robert G)
0.49%
FNY Investment Advisers LLC
0.18%
Benton (Andrew K. J.D.)
0.08%
Other
90.93%
Tipo
Accionista
Proporción
Private Equity
5.27%
Hedge Fund
3.07%
Individual Investor
0.63%
Investment Advisor/Hedge Fund
0.18%
Investment Advisor
0.04%
Other
90.81%
Participación institucional
Hora de actualización: lun., 24 de feb
Hora de actualización: lun., 24 de feb
Periodo de informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
35
151.14K
9.19%
-181.20K
2024Q4
41
152.48K
11.69%
-180.25K
2024Q3
42
173.09K
26.96%
+116.42K
2024Q2
41
44.94K
12.13%
-919.00
2024Q1
43
31.95K
18.34%
-413.00
2023Q4
44
15.51K
10.50%
-18.28K
2023Q3
49
27.39K
26.75%
-10.01K
2023Q2
49
42.64K
49.41%
+30.89K
2023Q1
50
17.95K
33.35%
+9.03K
2022Q4
49
6.68K
34.88%
+1.19K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Perceptive Advisors LLC
86.67K
5.27%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
50.00K
3.04%
+50.00K
--
Dec 31, 2024
Gower (Robert G)
8.13K
0.49%
--
--
Mar 07, 2025
FNY Investment Advisers LLC
3.00K
0.18%
+3.00K
--
Dec 31, 2024
Benton (Andrew K. J.D.)
1.33K
0.08%
--
--
Mar 07, 2025
Chang (William H C)
722.00
0.04%
-1.33K
-64.85%
Mar 07, 2025
UBS Financial Services, Inc.
595.00
0.04%
-6.92K
-92.08%
Dec 31, 2024
Tower Research Capital LLC
438.00
0.03%
+8.00
+1.86%
Dec 31, 2024
Kirkpatrick (D. Lynn)
107.00
0.01%
+1.00
+0.94%
Mar 07, 2025
BlackRock Institutional Trust Company, N.A.
64.00
0%
-1.00
-1.54%
Dec 31, 2024
Ver más
ETF relacionados
Nombre
Proporción
No datos encontrados
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
No datos encontrados
División de acciones
Fecha
Tipo
Relación
Dec 03, 2024
Merger
15<1
Dec 03, 2024
Merger
15<1
Dec 03, 2024
Merger
15<1
Dec 03, 2024
Merger
15<1
Mar 30, 2023
Merger
12<1
Mar 30, 2023
Merger
12<1
Fecha
Tipo
Relación
Dec 03, 2024
Merger
15<1
Dec 03, 2024
Merger
15<1
Dec 03, 2024
Merger
15<1
Dec 03, 2024
Merger
15<1
Mar 30, 2023
Merger
12<1
Mar 30, 2023
Merger
12<1
Mar 30, 2023
Merger
12<1
Mar 30, 2023
Merger
12<1
Oct 27, 2022
Merger
20<1
Oct 27, 2022
Merger
20<1
Ver más